The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis

CNS Drugs

Volumn 26, Issue 4, 2012, Pages 297-307

  Häuser, Winfried ^a,e   Wolfe, Frederick ^b,c   Tölle, Thomas ^d   Üçeyler, Nurcan ^e   Sommer, Claudia ^e  

^a Department of Internal Medicine I   (Germany)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amitriptyline; Antidepressants; Duloxetine; Fibromyalgia; Meta analysis; Milnacipran; Quality of life; Serotonin uptake inhibitors; Tricyclic antidepressants.

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; PAROXETINE; PLACEBO; PROTRIPTYLINE; REBOXETINE; TRIMIPRAMINE; VENLAFAXINE;

ANOREXIA; ANXIETY DISORDER; CELL HETEROGENEITY; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; INSOMNIA; LIVER INJURY; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SLEEP; SLEEP DISORDER; SOMNOLENCE; SUICIDE; SYSTEMATIC REVIEW; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; FIBROMYALGIA; HUMANS; PATIENT DROPOUTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84859089938     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11598970-000000000-00000     Document Type: Review

References (49)

1. Häuser W, Zimmer C, Felde E, et al. What are the key symptoms of fibromyalgia syndrome? Results of a survey of the German Fibromyalgia Association [in German]. Schmerz 2008; 22: 176-83
2. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600-10
3. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997; 40: 1553-5
4. Winkelmann A, Perrot S, Schaefer C, et al. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy 2011; 9: 125-36
5. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007 Mar 17; 369: 946-55 (Pubitemid 46400832)
6. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed 2007; 78: 88-95
7. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006; 12: 124-8 (Pubitemid 44314970)
8. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35
9. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 1863-4
10. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010; 39: 448-55
11. Sommer C, Häuser W, Gerhold K, et al. Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain [in German]. Schmerz 2008; 22 (3): 267-82
12. Bradley LA. Pathophysiology of fibromyalgia. Am J Med 2009; 122 (12 Suppl.): S22-30
13. Wolfe F. Fibromyalgia wars. J Rheumatol 2009; 36 (4): 671-8
14. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007 Mar 9; 8: 27
15. Marschall U, Arnold B, Häuser W. Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer Health Insurance (BEK) from 2008-2009 [in German]. Schmerz 2011; 25: 402-10
16. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome: pain in adults and children. APS Clinical Practice Guideline Series No. 4. Glenview (IL): American Pain Society, 2005
17. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536-41 (Pubitemid 351498437)
18. Häuser W, Eich W, Herrmann M, et al. Fibromyalgia syndrome: classification, diagnosis, and treatment. Dtsch Arztebl Int 2009; 106: 383-91
19. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome: a systematic review. Eur J Pain 2010; 14: 5-10
20. Briley M. Drugs to treat fibromyalgia: the transatlantic difference. Curr Opin Inves Drugs 2010; 11: 16-8
21. Häuser W, Petzke F, Üçeyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011; 50: 532-43
22. Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008; 68: 2611-32
23. Chan HN, Fam J, Ng BY. Use of antidepressants in the treatment of chronic pain. Ann Acad Med Singapore 2009; 38: 974-9
24. Mease PJ, Clauw DJ, Christensen R, et al., OMERACT Fibromyalgia Working Group. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol 2011; 38: 1487-95
25. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58
26. Häuser W, Bernardy K, Uçeyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301: 198-209
27. Furukawa TA, Cipriani A, Barbui C, et al. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005; 20: 49-52 (Pubitemid 40105550)
28. van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 2003; 28: 1290-9 (Pubitemid 36734620)
29. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988
30. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0, updated March 2011 [online]. Available from URL: http://www.cochrane-handbook.org/ [Accessed 2011 Dec 6]
31. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1-8
32. Kelly J. Pfizer stops work on esreboxetine for FM [online]. Available from URL: http://www.mskreport.com/articles.cfm?articleID=3293 [Accessed 2011 Feb 23]
33. Häuser W, Bartram C, Bartram-Wunn E, et al. Systematic review: adverse events attributable to nocebo in randomised controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy. Clin J Pain. Epub 2012 Feb 14
34. Amanzio M, Corazzini LL, Vase L, et al. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261-9
35. Drugs information online. Duloxetine [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022516lbl.pdf [Accessed 2011 Aug 15]
36. Drugs information online. Milnacipran [online]. Available from URL: http://www.drugs.com/pro/savella.html [Accessed 2011 Aug 15]
37. Drugs information online. Fluoxetine [online]. Available from URL: http://www.drugs.com/pro/fluoxetine.html [Accessed 2011 Aug 15]
38. Drugs information online. Paroxetine [online]. Available from URL: http://www.drugs.com/pro/paxil.html [Accessed 2011 Aug 15]
39. Drugs information online. Amitriptyline [online]. Available from URL: http://www.drugs.com/pro/amitriptyline.html [Accessed 2011 Aug 15]
40. Häuser W, Bartram-Wunn E, Bartram C, et al. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy: magnitude and patient-related predictors. Pain 2011; 152: 1709-17
41. Ernst E, Herxheimer A. The power of placebo. BMJ 1996; 313: 1569-70 (Pubitemid 27010645)
42. Walitt B, Fitzcharles MA, Hassett AL, et al. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol 2011; 38: 2238-46
43. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or with out major depressive disorder. Pain 2005; 119: 5-15 (Pubitemid 41752960)
44. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432-44
45. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol 2009; 24 Suppl. 1: S19-23
46. Arnold LM, Clauw DJ. Fibromyalgia syndrome: practical strategies for improving diagnosis and patient outcomes. Am J Med 2010; 123: S2
47. Häuser W, Klose P, Langhorst J, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2010; 12: R79
48. Langhorst J, Musial F, Klose P, et al. Efficacy of hydrotherapy in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Rheumatol (Oxford) 2009; 48: 1155-9
49. Häuser W, Bernardy K, Offenbächer M, et al. Efficacy of multicomponent treatment of fibromyalgia syndrome: a meta-analysis of randomised controlled trials. Arthritis Rheum 2009; 61: 216-24